Trials / Completed
CompletedNCT01245049
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children
Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 3 and 4-year-old Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 387 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 3 Years – 4 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM Polio to that of Sanofi Pasteur MSD's RepevaxTM, when co-administered with a second dose of PriorixTM, in healthy 3 and 4-year-old children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Boostrix PolioTM | Single dose, intramuscular administration. |
| BIOLOGICAL | RepevaxTM | Single dose, intramuscular administration. |
| BIOLOGICAL | PriorixTM | Single dose, intramuscular or subcutaneous administration. |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-03-27
- Completion
- 2012-04-02
- First posted
- 2010-11-22
- Last updated
- 2018-08-17
- Results posted
- 2017-07-05
Locations
13 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01245049. Inclusion in this directory is not an endorsement.